Research programme: antibacterials - Valevia Pharmaceuticals

Drug Profile

Research programme: antibacterials - Valevia Pharmaceuticals

Alternative Names: AVX 13616; AVX 13619; VAL 301; Vancomycin-resistant enterococci (VRE) therapeutics - Novita Healthcare; VRIs - Novita Healthcare

Latest Information Update: 01 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avexa
  • Developer Valevia Pharmaceuticals
  • Class Amino acids; Naphthalenes; Small molecules
  • Mechanism of Action Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium-difficile-infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections

Most Recent Events

  • 01 Feb 2018 Preclinical trials in Clostridium difficile infections in United Kingdom (PO) (Valevia website, February 2018)
  • 01 Feb 2018 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in United Kingdom (Intranasal) (Valevia website, February 2018)
  • 01 Feb 2018 Preclinical trials in Skin and soft tissue infections in United Kingdom (Topical) (Valevia website, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top